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Abstract: Patient adherence to many osteoporosis treatments, primarily bisphosphonates, is 
generally poor, thus leading to a significant reduction in antifracture efficacy. Patient perceptions 
about the necessity of the prescribed medication to treat osteoporosis and the concerns about the 
potential adverse effects are important and potentially modifiable determinants of adherence, in 
addition to other factors, such as difficult dosing regimens and high dosing frequency. Denosumab 
(Dmab) is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB 
ligand (RANKL), which, through the prevention of the RANKL/RANK interaction, inhibits 
osteoclast-mediated bone resorption and significantly reduces the risk of vertebral, nonverte-
bral, and hip fractures. It is administered subcutaneously every 6 months for the treatment of 
postmenopausal osteoporosis. Preference and adherence to Dmab treatment were assessed in 
various clinical trials. Although with some limitations, available data suggest that Dmab is 
preferred to bisphosphonates, produces greater satisfaction than bisphosphonates, and would be 
preferentially chosen for long-term treatment. Moreover, patient perceptions about the necessity 
of Dmab treatment clearly outweigh the concerns about the injections, and positive beliefs about 
treatment positively influence medication-taking behavior. According to these data, Dmab may 
represent a reasonable alternative to bisphosphonates, particularly for osteoporotic women in 
whom a suboptimal or even poor adherence to oral treatments is expected. 
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Introduction
Denosumab (Dmab) is a fully human monoclonal antibody against the receptor acti-
vator of nuclear factor-κB ligand (RANKL), a molecule that is crucial for the forma-
tion, function, and survival of osteoclasts.1 Dmab binds RANKL with high affinity 
and specificity, and inhibits the RANKL/RANK interaction, thus reversibly reducing 
osteoclast-mediated bone resorption. In phase 1 and phase 2 studies, Dmab was dem-
onstrated to decrease bone turnover and to increase bone mineral density (BMD),2–5 
and in the FREEDOM trial (Fracture REduction Evaluation of Denosumab in Osteo-
porosis every six Months, NCT00089791), a randomized placebo-controlled phase 3 
study, the subcutaneous administration of Dmab 60 mg every 6 months for 36 months 
significantly reduced the risk of vertebral and nonvertebral fractures, and reduced 
the risk of hip fracture in postmenopausal women with osteoporosis.6 Moreover, in 
the open-label extension of this study, Dmab therapy beyond the third year of treat-
ment was associated with a further reduction in nonvertebral fracture rate, and was 
associated with a continued low vertebral fracture rate that persisted through 8 years 
of continuous administration, with an overall safety profile that remained consistent 
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over time.7 On the basis of available evidence, in 2010, 
Dmab was approved for the treatment of postmenopausal 
osteoporosis, thus becoming a further therapeutic option for 
the reduction of fracture risk in addition to the other available 
antiresorptive therapies (ie, bisphosphonates and selective 
estrogen receptor modulators) and the anabolic teriparatide.8 
The available studies comparing the effect on BMD and bone 
turnover of Dmab and bisphosphonates, which are the most 
frequently used agents for the management of osteoporosis, 
showed significantly greater gains in BMD at all measured 
skeletal sites9–13 and greater reduction in bone turnover9–12 
with Dmab compared to bisphosphonates with a similar 
safety profile. However, both bisphosphonates and Dmab, in 
association with calcium and vitamin D, appear to be about 
equally effective in clinical trials in reducing the risk of 
fragility fractures,14 which represent a considerable problem 
of public health, considering the increasing fracture-related 
morbidity, mortality, and medical costs in many regions of 
the world.15
It must be considered, however, that any therapy, even if 
proved to be effective in clinical trials, requires adherence to 
achieve successful treatment outcomes. Adherence is a term 
that usually encompasses two different concepts: persistence 
and compliance. Persistence is the duration of time from 
initiation to discontinuation of therapy, while compliance 
is the degree to which a patient takes the medication as pre-
scribed.16 Accordingly, nonpersistence and noncompliance 
are usually defined as a gap in therapy greater than 90 days 
and a medication taken less than 80% of possible treatment 
days, respectively.16 Adherence to osteoporosis treatments is 
particularly challenging for health care professionals treat-
ing osteoporosis. Indeed, persistence and compliance with 
osteoporosis therapies are generally poor, thus leading to a 
significant reduction in their antifracture efficacy,17 which in 
turn leads to increased human and economic costs.18 In order 
to understand the extent of the problem, it is worth explain-
ing that previous studies showed that one-third to one-half 
of treated patients are not adherent to oral bisphosphonate 
treatment,19 and that the majority of patients discontinue 
oral bisphosphonate treatment within 1 year,17,19 with a 
mean persistence of only 184 days.17 In comparison with 
oral dosing regimens, persistence seems to be greater with 
an intravenous bisphosphonate administered less frequently, 
like the annual infusion of zoledronic acid, but it is anyway 
suboptimal. Indeed, a variable proportion of patients from 
one-third to two-thirds across studies did not receive a second 
administration of the drug, often because of adverse effects 
(postinfusion syndrome).20–22 These findings are due to the 
fact that treatment adherence among patients with chronic 
diseases like osteoporosis depends on various factors, among 
which difficult dosing regimens, high dosing frequency, 
and the occurrence of side effects play a significant role in 
reducing compliance and persistence. Moreover, patient per-
ception about the necessity of the prescribed medication to 
treat osteoporosis and their concerns about potential adverse 
effects are important and potentially modifiable determinants 
of adherence, especially if clarified and addressed at the 
beginning of the treatment. Finally, understanding patient 
preference may be a strategy to improve adherence to 
osteoporosis therapy, since a lower treatment satisfaction is 
associated with an increased risk of discontinuing or switch-
ing the ongoing osteoporosis medication, as compared with 
a higher treatment satisfaction.23 
In this review, we will focus on the results of studies that 
investigated patient preference and adherence to Dmab for 
the treatment of postmenopausal osteoporosis in comparison 
with alternative osteoporosis therapies, especially bisphos-
phonates, in order to establish who can take more advantage 
of Dmab therapy, to understand the possible factors that influ-
ence medication-taking behavior, and to discover potential 
strategies for improving adherence.
Patient preference for Dmab
Patient preference to and satisfaction with a specific drug 
are important determinants of adherence to therapies for 
chronic diseases, including osteoporosis.23,24 Preference 
is a relative index of desirability, and it can be measured 
as a choice between alternatives or scaled as a degree of 
desirability,25 while treatment satisfaction measures the 
degree to which patient expectations with different features 
of the ongoing treatment (eg, perceived efficacy, presence 
and severity of side effects, convenience, and bother with 
treatment) are met.25
Available studies typically compared patient preference 
to and satisfaction with Dmab versus bisphosphonates, 
especially alendronate, which is usually the first-line medica-
tion for the treatment of postmenopausal osteoporosis.26–28 
Since existing questionnaires assessing preference to and 
satisfaction with osteoporosis treatments were considered 
inadequate for the comparison between a weekly oral tablet 
and a 6-monthly subcutaneous injection, a new tool, the Pref-
erence and Satisfaction Questionnaire (PSQ), was developed 
to compare Dmab and alendronate.25 The PSQ consists of 
34 items that explore preference (the treatment choice made 
by a patient), satisfaction (the degree to which the features of 
a specific drug actually meet the patient expectations), and 
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finally, bother (the degree to which the patient is disturbed 
by certain features of the treatment).25
In the Determining Efficacy: Comparison of Initiating 
DEnosumab versus alendronate (DECIDE) trial and the 
Study of Transitioning from AleNdronate to Denosumab 
(STAND), two international, double-blind, double-dummy, 
randomized, phase 3 head-to-head trials comparing Dmab 
with alendronate,9,10 PSQ was completed after 12 months 
of treatment or upon study discontinuation.26 Among the 
subjects who expressed a preference, significantly more 
patients, who were blinded to their treatment assignment, 
preferred the injection over the tablet, and were more satis-
fied overall and with the dosing frequency of a 6-monthly 
injection over a weekly tablet after 12 months of treatment. 
Moreover, more patients indicated that they would choose 
the 6-monthly injection, which was better fitted to their life-
styles, for long-term use or continuation of treatment. Finally, 
among patients who expressed bother with treatments, more 
patients found that the weekly tablet was more bothersome 
than the 6-monthly injection.26
A subsequent multicenter, randomized, open-label, 
2-year crossover trial, the Denosumab Adherence Prefer-
ence Satisfac tion (DAPS) study,28 enrolled drug-naïve post-
menopausal women with low BMD, who were randomized 
in one of two treatment sequences: Dmab subcutaneously 
every 6 months for 1 year followed by alendronate orally 
once weekly for 1 year, or vice versa. At each follow-up 
visit, subjects completed questions about preference, sat-
isfaction, and bother, which were taken from the PSQ. At 
baseline and at 6 months, subjects reported lower mean 
scores concerning preference for alendronate than for Dmab, 
at 12 months significantly more subjects treated with Dmab 
than with alendronate reported to be either satisfied or quite 
satisfied with the dosing frequency, route of administration, 
convenience, and expressed overall satisfaction with the 
ongoing Dmab treatment.27 The final results from both years 
of the DAPS study further confirmed the data obtained before 
the crossover: at the end of the study, 92.4% of subjects 
preferred subcutaneous Dmab injections over alendronate 
tablets, and 91.2% of subjects said that they would choose 
Dmab injections for long-term treatment. In addition, at 
24 months, regardless of the treatment sequence, a greater 
proportion of subjects reported that they were quite/very 
satisfied with the attributes of Dmab compared with those 
of alendronate.28
A recent study evaluated the change in treatment satis-
faction in women with postmenopausal osteoporosis who 
were suboptimally adherent with prior daily or weekly 
bisphosphonate therapy and who were shifted to subcuta-
neous 6-monthly Dmab or monthly oral bisphosphonate 
(ibandronate or risedronate).29 In such study, a post hoc analy-
sis of the results of two international, multicenter, randomized, 
open-label studies that had BMD and bone turnover varia-
tions as primary endpoints,12,13 was performed. The change 
in treatment satisfaction was assessed using the Treatment 
Satisfaction Questionnaire for Medication (TSQM), a tool 
validated for the measure of patient satisfaction with treat-
ments of different chronic diseases and which consists of 14 
items to assess an individual’s perception of four domains 
of treatment satisfaction: 1) effectiveness, 2) side effects, 
3) convenience, and 4) global satisfaction.30 The results of the 
study showed that osteoporotic postmenopausal women sub-
optimally adherent with oral daily or weekly bisphosphonate 
therapy, who switched to Dmab or monthly bisphosphonate 
treatment, reported greater satisfaction in all four domains of 
TSQM in both treatment groups at 6 and 12 months, but that 
these positive changes were significantly greater in patients in 
the Dmab group compared to those in patients in the monthly 
bisphosphonate group at all post-baseline time points.29 
Whereas patient preference to 6-monthly Dmab injec-
tions versus oral weekly or monthly bisphosphonates was 
not surprising in relation to the more acceptable route of 
administration and the less frequent dosing regimen of the 
6-monthly treatment option, patient preference between 
Dmab and another long-acting injectable therapy, such as 
zoledronic acid, could be less obvious. However, while 
several studies clearly demonstrated that patients preferred 
once yearly intravenous infusion of zoledronic acid rather 
than oral weekly bisphosphonates,31–33 a direct comparison in 
terms of patient satisfaction between Dmab and zoledronic 
acid for the treatment of postmenopausal osteoporosis is 
lacking. A recent retrospective study on a limited cohort of 
patients reported a statistically similar patient satisfaction 
between a group of patients treated with Dmab and another 
one treated with zoledronic acid,34 but the small sample size 
and the design of the study (ie, each patient experienced only 
one of the two treatments without any experience of the other 
treatment) do not permit us to draw clear conclusions.
Other parameters closely related to treatment satisfaction 
and preference, which could influence patient medication-
taking behavior, are patient perceptions about a therapy in 
terms of the perceived necessity of the prescribed medication 
to treat a specific condition and concerns about potential 
adverse effects. A validated tool to assess these beliefs 
and concerns can be found in the Beliefs about Medicines 
Questionnaire (BMQ), which consists of 22 questions in the 
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following major domains: 1) the necessity of the prescribed 
medication to treat osteoporosis in that moment or in the 
future; 2) concerns about potential side effects of taking the 
prescribed medication; and 3) preference for one drug over 
the other.35
At baseline in the DAPS study,27,28 when women were 
naїve to therapy, necessity and concerns scores were similar 
between groups. Subsequently, subject beliefs about the 
necessity for the prescribed treatment were significantly 
higher for Dmab than for alendronate at 6 months, but not 
at the following visits. Subject concerns about potential 
side effects were significantly lower for Dmab than for 
alendronate at the follow-up visits after the cross-over, when 
patients had experienced both forms of treatment administra-
tion, but not at previous time points.27,28 These variations in 
subject perceptions about treatment resulted in a significantly 
higher necessity–concerns differential (NCD) (ie, how much 
treatment necessity outweighs treatment concerns) for Dmab 
compared with alendronate at 6 months for both treatment 
years.36 Finally, the BMQ survey in the DAPS study provided 
significantly lower mean preference scores for alendronate 
than for Dmab at every visit, consistent with the preference 
scores of the PSQ.27,28
Adherence to Dmab
Many of the studies, which investigated preference for and 
satisfaction with Dmab, also evaluated adherence to the treat-
ment, overall or in comparison with oral bisphosphonates, 
especially alendronate. Unfortunately, studies specifically 
designed to compare adherence to Dmab versus zoledronic 
acid are still lacking.
In the DECIDE and the STAND studies, where partici-
pants were strictly followed up every 3 months, compliance 
at 12 months (both injections received and $80% of the oral 
tablets) was 93% and 94%, respectively, with Dmab and 91% 
and 94%, respectively, with alendronate.9,10
In the DAPS study, adherence, ie, both compliance 
(both Dmab injections 6 months ±4 weeks apart or $80% 
of alendronate tablets taken) and persistence (both Dmab 
injections or greater than two alendronate doses in the last 
month and completion of the treatment period), was assessed 
separately for each treatment year.27,28 By the end of the first 
12 months, 88.1% of postmenopausal women were adherent 
to Dmab and 76.6% of patients were adherent to alendronate, 
while after the crossover, the adherence rate was 92.5% for 
Dmab and 63.5% for alendronate. A 46% and 80% relative 
risk reduction of nonadherence was calculated with Dmab 
compared to alendronate in the first and in the second year, 
respectively.27,28 The increase of nonadherence for alen-
dronate-treated subjects after the crossover from Dmab, and 
conversely, the further decrease of nonadherence for Dmab-
treated subjects after the crossover from alendronate, suggest 
a possible treatment sequence effect: a weekly dosing fre-
quency may be more difficult to follow after a biannual dos-
ing frequency than the opposite treatment sequence. DAPS 
investigators also examined whether the subjects’ perception 
of their osteoporosis treatment and the treatment preferences 
influenced adherence.36 They found that at the beginning of 
the second year of treatment participant perception, as 
 measured by BMQ scores, was a significant predictor of 
nonadherence. Indeed, as necessity scores increased, the 
odds of nonadherence decreased, and conversely, as concerns 
scores increased, the odds of nonadherence increased. These 
trends were reflected in the NCD. Indeed, higher NCD scores 
were significantly associated with lower odds of nonadher-
ence, thus suggesting that positive perceptions of treatment 
positively influence medication-taking behavior.36
By extension, it seems feasible that understanding the 
factors that influence patient perceptions of osteoporosis treat-
ments may result in an improved educational effort to increase 
adherence. In relation to this hypothesis, a successive study, 
although with several limitations, showed that in osteoporotic 
patients starting with a first Dmab injection, a positive feed-
back given to the patient already 6 months thereafter, based 
on the demonstration through a careful medical explanation 
of a rapid and highly significant BMD increase and on a 
good safety profile, was able to guarantee in 99% of patients 
the willingness to accept a second injection, thus reinforcing 
the role of patient perceptions and of their assessment during 
doctor–patient interactions on adherence to treatment.37
Several studies on medication-taking behavior of patients 
receiving Dmab are now ongoing, and data available so far 
confirm a high adher ence to this 6-monthly subcutaneous 
treatment.38,39 The 12-month interim results of a European 
noninterventional study involving Germany, Austria, Greece, 
and Belgium showed that 82.7%–89.3% of patients received a 
second Dmab injection within 6 months ±4 weeks, and there-
fore, these patients were considered adherent to treatment,38 a 
proportion of patients significantly greater than that observed 
in similar studies on bisphosphonates.17,19 In all four countries, 
these percentages increased as the permissible time window 
was extended, and up to 95.3% of patients received a second 
administration within 6 months ±8 weeks.38 At baseline, 
all participants completed the Morisky 8-Item Medication 
Adherence Scale (MMAS-8) questionnaire, a tool used to 
measure the probability of adherence.40 However, although 
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the majority of patients had a low or medium score for adher-
ence to prior treatments, their adherence to Dmab was high 
anyway, suggesting that some features of Dmab, such as the 
dosing schedule, may have positively influenced adherence 
behavior. No baseline variables were found to be significantly 
associated with persistence in the four countries, probably 
because of the high percentages observed and because of 
the different health care systems in the individual countries; 
nevertheless, in some countries, several significant associa-
tions were identified. Indeed, parental history of hip fracture 
was associated with higher persistence, while increased age, 
decreased mobility, and increased distance to the clinic were 
correlated with lower persistence.38
Finally, interim results of a 24-month multicenter, pro-
spective, single-arm observational study in the US and 
Canada showed that at 12 months, 81.9% of patients were 
persistent with Dmab (ie, they received a second Dmab injec-
tion within 6 months ±8 weeks).39 As already described in 
another study,38 this percentage changed as the window was 
modified (from 74.8% of patients with a 4-week window to 
84.8% of patients with a 12-week window). In this popula-
tion, several baseline variables were found to be significantly 
associated with persistence among US patients and others 
among Canadian patients.39 In particular, it is worth signal-
ing that US patients with greater NCD obtained by means 
of BMQ had a higher odds ratio for persistence,32 further 
confirming the role of patient perceptions of a specific medi-
cation in influencing medication-taking behavior, as already 
described in previous studies.23,36,37
Limitations
Several limitations must be considered in the interpretation 
of these trials. Firstly, participants enrolled in a clinical trial 
may differ from patients seen in real-life clinical practices. 
This difference may be observable to a greater extent in 
randomized clinical trials, where patients are regularly fol-
lowed up by a skilled health care professional according 
to a precise study protocol. However, the participation in 
any prospective study, even observational, may influence 
patients’ behavior, potentially leading to an overestimation 
of adherence to and preference for a specific treatment. 
This observation is supported by the finding that the rates of 
bisphosphonate adherence observed in the studies cited so 
far are meaningfully higher than rates observed in previous 
retrospective observational reports (less than half in the first 
year).17,19 The main reasons that may explain this phenom-
enon are the willingness of subjects to participate in a study 
and thus to accept the treatment offered, and the awareness 
of patients that their medication-taking behavior is being 
monitored. These two factors, differently from real-world 
behaviors, eliminate primary nonadherence patient behaviors 
in trials (ie, the refusal of a medication at first prescription). 
Moreover, in the clinical trials, participants are selected 
according to given inclusion criteria, and this aspect may 
limit the generalizability of results.
Secondly, in many of the cited studies,26–29,36–39 a conflict 
of interest cannot be excluded, and the provision of a drug to 
study participants by the study sponsor may have concealed 
the possible influences of treatment cost and accessibility 
on patient preference and adherence. Nevertheless, although 
several studies suggested that Dmab is cost-effective as com-
pared to bisphosphonates,41–45 it must be considered that the 
effect of these aspects may be very difficult to assess since 
health care and reimbursement systems vary extensively 
between countries, and thus studies performed in different 
regions of the world become scarcely comparable.
Thirdly, the use of 1- or 2-year treatment periods in the 
cited trials27,28,38,39 may limit conclusions about long-term 
adherence to treatment, although a previous meta-analysis 
on bisphosphonate treatment suggests that nonadherence 
usually occurs shortly after treatment initiation.19
Conclusion
In spite of these limitations, available data suggest that, 
in comparison with bisphosphonates, postmenopausal 
women report greater preference to and satisfaction with 
Dmab, both overall and with its dosing frequency and 
route of administration, and they would choose Dmab over 
bisphosphonates for long-term osteoporosis treatment.26–29 
Moreover, patient beliefs about the necessity of osteoporo-
sis treatment and patient concerns about potential adverse 
events appear higher and lower, respectively, with Dmab 
than with bisphosphonates. This situation results in greater 
NCD scores, indicating that in patient perceptions, treatment 
necessity clearly outweighs concerns about Dmab.27,28,36 
Furthermore, clinical trials showed that adherence among 
women treated with Dmab was consistently .80% across 
studies;9,10,13,27,28,37–39 therefore, significantly higher adherence 
was shown in women treated with Dmab than in women 
treated with bisphosphonates, even when bisphosphonates 
were administered once monthly or intravenously.17,19–22 
This different medication-taking behavior appears to be 
even more pronounced in patients previously treated, often 
sub-optimally, with bisphosphonates.12,13,28,38
Although in clinical trials an overestimation of adherence 
is conceivable, it must be considered that the adherence to 
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Dmab requires only a 6-monthly visit, while the adherence to 
oral bisphosphonates requires the patient self-administration 
of tablets according to a correct dosing schedule and in the 
correct way. Therefore, it is possible that in clinical practice, 
the differences between Dmab and oral bisphosphonates in 
term of compliance and persistence may be even higher, 
although additional real-life studies are needed to confirm 
this assumption. Moreover, patient perception about treat-
ment seems to influence medication-taking behavior,36,39 and 
during treatment follow-up, positive reinforcement based on 
the evidence of actual successful treatment outcomes, such as 
the BMD increase9–13 or bone turnover suppression,9–12 could 
help to further improve patient adherence.37 Indeed, due to 
the asymptomatic nature of osteoporosis, until a fracture 
occurs or even later, the patient could easily underestimate 
the importance of osteoporosis medication, resulting in poor 
adherence and therefore an increased risk of fracture.
In conclusion, current evidence underlines the neces-
sity to personalize osteoporosis treatment, taking patient 
preference into account, especially in regards to frequency 
and route of administration. Current evidence also draws 
attention to patient beliefs at the initiation of therapy and 
during follow-up. These efforts are addressed to improve 
adherence to osteoporosis treatment and, as a consequence, to 
achieve more successful treatment outcomes, thus positively 
impacting on the cost-effectiveness of the chosen drug.45 
From this perspective, according to the data demonstrating 
a better adherence to Dmab compared to other osteoporosis 
treatments, especially bisphosphonates, Dmab may represent 
a reasonable and effective alternative to bisphosphonates, 
particularly for osteoporotic women in whom a suboptimal 
or even poor adherence to oral treatments is expected.
Further studies are required in the future to assess 
long-term adherence and preference to Dmab in real-world 
clinical practices, to evaluate its long-term safety, and to 
assess its effectiveness as compared head-to-head with 
bisphosphonates.
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